SAGE - Sage Therapeutics, Inc.
After hours:
Chart Events
Triple Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 49.56 |
| Open | 50.04 |
| Bid | 48.07 x 900 |
| Ask | 51.43 x 3000 |
| Day's Range | 48.75 - 50.24 |
| 52 Week Range | 30.67 - 54.86 |
| Volume | |
| Avg. Volume | 514,626 |
| Market Cap | 2.977B |
| Beta (5Y Monthly) | 1.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.41 |
| Earnings Date | Jul 31, 2023 - Aug 04, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 60.82 |
Fair Value
Related Research
Insider Monkey15 Most Suicidal States in America
In this article, we are going to discuss the 15 most suicidal states in America. You can skip our detailed analysis of global suicide statistics, suicide rates in the U.S., financial cost of suicide and biotech companies working to treat mental heath issues and go directly to 5 Most Suicidal States in America. Every year, over […]
Simply Wall St.Elizabeth Barrett At Sage Therapeutics Tops Up Holding By US$51k \
Even if it's not a huge purchase, we think it was good to see that Elizabeth Barrett, a Sage Therapeutics, Inc...
Business WireSage Therapeutics to Present at Upcoming May Investor Conferences
CAMBRIDGE, Mass., May 03, 2023--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in May:
ZacksSage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.60% and 35.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireSage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass., May 02, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2023.
ZacksEarnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Sage Therapeutics, Inc. (NASDAQ:SAGE) insiders placed bullish bets worth US$752k in the last 12 months
In the last year, multiple insiders have substantially increased their holdings of Sage Therapeutics, Inc...
ZacksAnalysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireSage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
CAMBRIDGE, Mass., April 18, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, May 2, 2023 at 8:00 a.m. ET to review first quarter 2023 financial results and discuss recent business updates.
Business WireSage Therapeutics to Present at the Stifel 2023 CNS Days
CAMBRIDGE, Mass., March 22, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 11:00 a.m. ET.
Business WireSage Therapeutics Appoints Jessica Federer to Board of Directors
CAMBRIDGE, Mass., March 16, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company’s Board of Directors.
ZacksSage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock?
Sage Therapeutics, Inc. (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Simply Wall St.
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Business WireSage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
CAMBRIDGE, Mass., March 08, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Business WireSage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
CAMBRIDGE, Mass., February 28, 2023--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET in Boston, MA.
Business WireSage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
CAMBRIDGE, Mass., February 22, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the European Medicines Agency (EMA) granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington’s disease (HD). SAGE-718 is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction. Multiple clinical studies are ongoing with SAGE-718 across several di
Insider MonkeySage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2022 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2022 Earnings Call Transcript February 16, 2023 Operator: Good morning. Welcome to the Sage Therapeutics’ Fourth Quarter and Full-Year 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Sage’s website at sagerx.com. This […]
ZacksSage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue Estimates
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -4.22% and 38.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireSage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
CAMBRIDGE, Mass., February 16, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.
ZacksSage and Biogen's NDA for Depression Drug Gets Priority Review
Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.
BenzingaSage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'
The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) zuranolone for major depressive disorder (MDD) and postpartum depression (PPD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of August 5, 2023. William Blair views the acceptance as an important milestone for the company. The analyst believes the granting of priority review, though not surprising, is an incremental positive
Business WireSage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
CAMBRIDGE, Mass., February 06, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The application has been granted priority revie
GlobeNewswireBiogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD)Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatme
Business WireSage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
CAMBRIDGE, Mass., February 02, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Thursday, February 16, 2023 at 8:00 a.m. ET to review fourth quarter and full year 2022 financial results and discuss recent business updates.
ZacksZacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB
XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB are part of the Zacks Investment Ideas article.